Therefore, even though we report findings of previously undiscovered pathogenic germline variants, particularly in BRCA1 and BRCA2, the potential clinical benefit of PARPi treatment in these drug-resistant patients at advanced stage of cancer remains unclear. Here, BRCA2 is linked to cancer.